2,7-disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation

Chemical Research in Toxicology

Volumn 24, Issue 11, 2011, Pages 1994-2003

  Wells Knecht, Kevin J ^a   Ott, Gregory R ^a   Cheng, Mangeng ^a   Wells, Gregory J ^a   Breslin, Henry J ^a   Gingrich, Diane E ^a   Weinberg, Linda ^a   Mesaros, Eugen F ^a   Huang, Zeqi ^a   Yazdanian, Mehran ^a   Ator, Mark A ^a   Aimone, Lisa D ^a   Zeigler, Kelli ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CP 6890550; CRIZOTINIB; DASATINIB; DICLOFENAC; GLUTATHIONE; IMATINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NILOTINIB; NVP TAE226; NVP TAE684; PARACETAMOL; PF 562271; PHOSPHOTRANSFERASE INHIBITOR; RUXOLITINIB; SAR 302503; SORAFENIB; TASOCITINIB; TG 101348; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; MASS SPECTROMETRY; METABOLITE; NONHUMAN; RAT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; BILE; BIOTRANSFORMATION; CHEMISTRY, PHARMACEUTICAL; CHROMANS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CLOZAPINE; DOGS; GLUTATHIONE; HAPLORHINI; HUMANS; MICE; MICROSOMES, LIVER; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRROLES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULFHYDRYL COMPOUNDS; THIAZOLIDINEDIONES; TRIAZINES;

EID: 81755164033     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx200304r     Document Type: Article

References (57)

1. Walgren, J. L., Mitchell, M. D., and Thompson, D. C. (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity Crit. Rev. Toxicol. 35, 325-361 (Pubitemid 40691298)
2. Nelson, S. D. (1982) Metabolic activation and drug toxicity J. Med. Chem. 25, 753-765 (Pubitemid 12056951)
3. Amacher, D. E. (2006) Reactive intermediates and the pathogenesis of adverse drug reactions: The toxicology perspective Curr. Drug Metab. 7, 219-229
4. Takakusa, H., Masumoto, H., Yukinaga, H., Makino, C., Nakayama, S., Okazaki, O., and Sudo, K. (2008) Covalent binding and tissue distribution/retention assessment of drugs associated with idiosyncratic drug toxicity Drug Metab. Dispos. 36, 1770-1779
5. Liebler, D. C. (2008) Protein damage by reactive electrophiles: targets and consequences Chem. Res. Toxicol. 21, 117-128 (Pubitemid 351219713)
6. Reid, A. B., Kurten, R. C., McCullough, S. S., Brock, R. W., and Hinson, J. A. (2005) Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes J. Pharmacol. Exp. Ther. 312, 509-516 (Pubitemid 40189547)
7. Kedderis, G. L. (1996) Biochemical basis of hepatocellular injury Toxicol. Pathol. 24, 77-83 (Pubitemid 26066422)
8. Uetrecht, J. (2008) Idiosyncratic drug reactions: past, present, and future Chem. Res. Toxicol. 21, 84-92 (Pubitemid 351219710)
9. Hinson, J. A., Roberts, D. W., and James, L. P. (2010) Mechanisms of acetaminophen-induced liver necrosis Handb. Exp. Pharmacol. 196, 369-405
10. Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., and Aleo, M. D. (2011) Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States Chem. Res. Toxicol. 24, 1345-1410
11. Hop, C. E. C. A, Kalgutkar, A., and Soglia, J. R. (2006) Importance of early assessment of bioactivation in drug discovery Annu. Rep. Med. Chem. 41, 369-381
12. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G., Naisbitt, D. J., Nelson, S., Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A., Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie, T. A. (2011) Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discovery 10, 292-306
13. Hansen-Moller, J. and Schmit, U. (1991) Rapid high-performance liquid chromatographic assay for the simultaneous determination of probenecid and its glucuronide in urine. Irreversible binding of probenecid to serum albumin J. Pharmaceut. Biomed. 9, 65-73
14. Bu, H. Z., Kang, P., Deese, A. J., Zhao, P., and Pool, W. F. (2005) Human in vitro glutathionyl and protein adducts of carbamazepine-10,11-epoxide, a stable and pharmacologically active metabolite of carbamazepine Drug Metab. Dispos. 33, 1920-1924 (Pubitemid 41697278)
15. Ma, S. and Zhu, M. (2009) Recent advances in applications of liquid chromatography-tandem mass spectrometry to the analysis of reactive drug metabolites Chem.-Biol. Interact. 179, 25-37
16. Gan, J., Harper, T. W., Hsueh, M. M., Qu, Q., and Humphreys, W. G. (2005) Dansyl Glutathione as a Trapping Agent for the Quantitative Estimation and Identification of Reactive Metabolites Chem. Res. Toxicol. 18, 896-903 (Pubitemid 40705457)
17. Gan, J., Ruan, Q., He, B., Zhu, M., Shyu, W. C., and Humphreys, W. G. (2009) In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation Chem. Res. Toxicol. 22, 690-698
18. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., and Okazaki, O. (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37, 1970-1977
19. Usui, T., Mise, M., Hashizume, T., Yabuki, M., and Komuro, S. (2009) Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins Drug Metab. Dispos. 37, 2383-2392
20. Ott, G. R., Wells, G. J., Thieu, T. V., Quail, M. R., Lisko, J. G., Mesaros, E. F., Gingrich, D. E., Ghose, A. K., Wan, W., Lu, L., Cheng, M., Albom, M. S., Angeles, T. S., Huang, Z., Aimone, L. D., Ator, M. A., Ruggeri, B. A., and Dorsey, B. D. (2011) 2,7-Disubstituted-pyrrolo[2,1- f ][1,2,4]triazines: New variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity J. Med. Chem. 54, 6328-6341
21. Garcia-Echeverria, C., Kanazawa, T., Kawahara, E., Masuya, K., Matsuura, N., Miyake, T., Ohmori, O., and Umemura, I. (2004) Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. WO 2004080980.
22. Cao, J. J., Hood, J., Lohse, D., Mak, C. C., McPherson, A., Noronha, G., Pathak, V., Renick, J., Soll, R. M., and Zeng, B. (2007) Preparation of bi-aryl 2,4-pyrimidinediamines as inhibitors of kinases. PCT Int. Appl. WO 2007053452.
23. Christensen, J. G. and Zou, Y. (2007) N-Piperidinyl-4-(pyridin-5-yl) pyrazole compounds and their preparation and method of treating abnormal cell growth. PCT Int. Appl. WO 2007066187.
24. Lin, Q., Meloni, D., Pan, Y., Xia, M., Rodgers, J., Shepard, S., Li, M., Galya, L., Metcalf, B., Yue, T. Y., Liu, P., and Zhou, J. (2009) Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction Org. Lett. 11, 1999-2002
25. Kath, J. C., Luzzio, M. J., Lagreca, S. D., and Patel, N. C. (2007) Preparation of salts and solvates of N-[3-[[[2-[(2,3-dihydro-2-oxo-1H-indol-5- yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl] -N-methylmethanesulfonamide for the treatment of abnormal cell growth. PCT Int. Appl. WO 2007063384.
26. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., and Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays J. Med. Chem. 47, 6658-6661 (Pubitemid 40053752)
27. Dieckhaus, C. M., Fernandez-Metzler, C. L., King, R., Krolikowski, P. H., and Baillie, T. A. (2005) Negative ion tandem mass spectrometry for the detection of glutathione conjugates Chem. Res. Toxicol. 18, 630-638 (Pubitemid 40563277)
28. Schäefer, M., Dray , M., Springer, A., Zacharias, P., and Meerholz, K. (2007) Radical cations in electrospray mass spectrometry: formation of open-shell species, examination of the fragmentation behavior in ESI-MSn and reaction mechanism studies by detection of transient radical cations Eur. J. Org. Chem. 5162-5174
29. Mautjana, N. A., Estes, J., Eyler, J. R., and Brajter-Toth, A. (2008) Antioxidant pathways and one-electron oxidation of dopamine and cysteine in electrospray and on-line electrochemistry electrospray ionization mass spectrometry Electroanalysis 20, 1959-1967
30. Stokes, A. H., Hastings, T. G., and Vrana, K. E. (1999) Cytotoxic and genotoxic potential of dopamine J. Neurosci. Res. 55, 659-665 (Pubitemid 29173480)
31. Nicolis, S., Zucchelli, M., Monzani, E., and Casella, L. (2008) Myoglobin modification by enzyme-generated dopamine reactive species Chem.-Eur. J. 14, 8661-8673
32. Rabinovic, A. D. and Hastings, T. G. (1998) Role of endogenous glutathione in the oxidation of dopamine J. Neurochem. 71, 2071-2078 (Pubitemid 28491563)
33. Oss, M., Kruve, A., Herodes, K., and Leito, I. (2010) Electrospray ionization efficiency scale of organic compounds Anal. Chem. 82, 2865-2872
34. Walker, D. P., Bi, F. C., Kalgutkar, A. S., Bauman, J. N., Zhao, S. X., Soglia, J. R., Aspnes, G. E., Kung, D. W., Klug-McLeod, J., Zawistoski, M. P., McGlynn, M. A., Oliver, R., Dunn, M., Li, J. C., Richter, D. T., Cooper, B. A., Kath, J. C., Hulford, C. A., Autry, C. L., Luzzio, M. J., Ung, E. J., Roberts, W. G., Bonnette, P. C., Buckbinder, L., Mistry, A., Griffor, M. C., Han, S., and Guzman-Perez, A. (2008) Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure-activity relationships and strategies for the elimination of reactive metabolite formation Bioorg. Med. Chem. Lett. 18, 6071-6077
35. Kalgutkar, A. S. (2011) Handling reactive metabolite positives in drug discovery: What has retrospective structure-toxicity analyses taught us? Chem.-Biol. Interact 192, 46-55
36. Kalgutkar, A. S., Griffith, D. A., Ryder, T., Sun, H., Miao, Z., Bauman, J. N., Didiuk, M. T., Frederick, K. S., Zhao, S. X., Prakash, C., Soglia, J. R., Bagley, S. W., Bechle, B. M., Kelley, R. M., Dirico, K., Zawistoski, M., Li, J., Oliver, R., Guzman-Perez, A., Liu, K. K. C., Walker, D. P., Benbow, J. W., and Morris, J. (2010) Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl) pyrido[4,3- d ]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis Chem. Res. Toxicol. 23, 1115-1126
37. Nguyen, T. L., Gruenke, L. D., and Castagnoli, N., Jr. (1979) Metabolic oxidation of nicotine to chemically reactive intermediates J. Med. Chem. 22, 259-263 (Pubitemid 9137315)
38. Yan, Z., Maher, N., Torres, R., and Huebert, N. (2007) Use of a trapping agent for simultaneous capturing and high-throughput screening of both "soft" and "hard" reactive metabolites Anal. Chem. 79, 4206-4214 (Pubitemid 46903174)
39. Li, X., He, Y., Ruiz, C. H., Koenig, M., and Cameron, M. D. (2009) Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways Drug Metab. Dispos. 37, 1242-1250
40. Bonvin, A., Mesnil, A., Nicolini, F. E., Cotte, L., Michallet, M., Descotes, J., and Vial, T. (2008) Dasatinib-induced acute hepatitis Leuk. Lymphoma 49, 1630-1632
41. Rea, D., Bergeron, A., Fieschi, C., Bengoufa, D., Oksenhendler, E., and Dombret, H. (2008) Dasatinib-induced lupus Lancet 372, 713-714
42. Brown, E. R. (1988) Quinonediimines, monoimines, and related compounds. In The Chemistry of the Quinonoid Compounds (Patai, S. and Rappoport, Z., Eds.) Vol. 2, pp 1231-1292, John Wiley & Sons, New York.
43. Nickel, U., Kemnitz, K., and Jaenicke, W. (1978) Kinetics and mechanism of the acid deamination of N-substituted quinone diimines measured with a multi-mixing, stopped-flow technique J. Chem. Soc. Perkins Trans. 2, 1188-1193
44. Hochstein, P. (1983) Futile redox cycling: implications for oxygen radical toxicity Fundam. Appl. Toxicol. 3, 215-217 (Pubitemid 14241865)
45. Joseph, P. and Jaiswal, A. K. (1998) NAD(P)H:quinone oxidoreductase 1 reduces the mutagenicity of DNA caused by NADPH:P450 reductase-activated metabolites of benzo(a)pyrene quinines Br. J. Cancer 77, 709-719 (Pubitemid 28077457)
46. Lau, S. S., Hill, B. A., Highet, R. J., and Monks, T. J. (1988) Sequential oxidation and glutathione addition to 1,4-benzoquinone: correlation of toxicity with increased glutathione substitution Mol. Pharmacol. 34, 829-836 (Pubitemid 19014405)
47. Monks, T. J., Highet, R. J., and Lau, S. S. (1988) 2-Bromo-(diglutathion- S-yl)hydroquinone nephrotoxicity: physiological, biochemical, and electrochemical determinants Mol. Pharmacol. 34, 492-500
48. Bolton, J. L., Trush, M. A., Penning, T. M., Dryhurst, G., and Monks, T. J. (2000) Role of quinones in toxicology Chem. Res. Toxicol. 13, 135-160 (Pubitemid 30169958)
49. Monks, T. J. and Jones, D. C. (2002) The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers Curr. Drug Metab. 3, 425-438 (Pubitemid 34778005)
50. Docampo, R., Moreno, S. N. J., and Mason, R. P. (1988) Generation of superoxide anion and hydrogen peroxide during redox cycling of 5-(4-nitrophenyl)penta-2,4-dienal by mammalian microsomes and enzymes Chem.-Biol. Interact. 65, 123-131
51. Kohno, Y., Kitamura, S., Yamada, T., Sugihara, K., and Ohta, S. (2005) Production of superoxide radical in reductive metabolism of a synthetic food-coloring agent, indigocarmine, and related compounds Life Sci. 77, 601-614 (Pubitemid 40726348)
52. Criddle, D. N., Gillies, S., Baumgartner-Wilson, H. K., Jaffar, M., Chinje, E. C., Passmore, S., Chvanov, M., Barrow, S., Gerasimenko, O. V., Tepikin, A. V., Sutton, R., and Petersen, O. H. (2006) Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells J. Biol. Chem. 281, 40485-40492 (Pubitemid 46041851)
53. Narayanan, P. K., Hart, T., Elcock, F., Zhang, C., Hahn, L., McFarland, D., Schwartz, L., Morgan, D. G., and Bugelski, P. (2003) Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment Cytometry, Part A 52A, 28-35 (Pubitemid 37522531)
54. Shenton, J. M., Chen, J., and Uetrecht, J. P. (2004) Animal models of idiosyncratic drug reactions Chem.-Biol. Interact. 150, 53-70 (Pubitemid 39441295)
55. Roth, R. A. and Ganey, P. E. (2011) Animal models of idiosyncratic drug-induced liver injury-current status Crit. Rev. Toxicol. 41, 723-739
56. Mesaros, E. F., Thieu, T. V., Wells, G. J., Zificsak, C. A., Wagner, J., Breslin, H. J., Tripathy, R., Diebold, J., McHugh, R., Wohler, A., Quail, M. R., Wan, W., Lu, L., Huang, Z., Albom, M. S., Angeles, T. S., Wells-Knecht, K. J., Aimone, L. D., Cheng, M., Ator, M. A., Ruggeri, B. A., Ott, G. R., and Dorsey, B. D. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1- f ][1,2,4]triazines: Identification of orally bioavailable, efficacious ALK inhibitor. J. Med. Chem., in press.
57. Weinberg, L. R., Albom, M. S., Angeles, T. S., Breslin, H. J., Gingrich, D. E., Huang, Z., Lisko, J. G., Mason, J. L., Milkiewicz, K. L., Thieu, T. V., Underiner, T. L., Wells, G. J., Wells-Knecht, K. J., and Dorsey, B. D. 2,7-Pyrrolo[2,1- f ][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation. Bioorg. Med. Chem. Lett., doi: 10.1016/j.bmcl.2011.10.032.